2021
Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials
Metzger AL, Appiah A, Wright CM, Jairam V, Amini A, Park HS, Welsh JW, Thomas CR, Verma V, Ludmir EB. Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials. International Journal Of Cancer 2021, 149: 1683-1690. PMID: 34173669, DOI: 10.1002/ijc.33719.Peer-Reviewed Original ResearchMeSH KeywordsAdultConflict of InterestFemaleHumansIndustryMaleMedical OncologyMultivariate AnalysisNeoplasmsRandomized Controlled Trials as TopicRegression AnalysisResearch PersonnelResearch Support as TopicUnited StatesConceptsClinical trialsMultivariable gamma regression analysesNational Clinical Trials NetworkPrincipal investigatorPhase III componentSystemic therapy trialsUS cooperative groupsClinical Trials NetworkCooperative groupsCancer clinical trialsGamma regression analysisSystemic therapySuch RCTsTherapy trialsRCTsTrials NetworkTrialsRegression analysisOne-thirdMedical journalsDrugs
2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials
Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials. Cancer 2020, 127: 709-719. PMID: 33119177, DOI: 10.1002/cncr.33269.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenCarcinoma, Non-Small-Cell LungHumansImmune Checkpoint InhibitorsLung NeoplasmsNetwork Meta-AnalysisRandomized Controlled Trials as TopicConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSingle-agent ICICell lung cancerPD-L1Lung cancerAdditional overall survival benefitsEfficacy of chemoimmunotherapyFirst-line ICIHigh PD-L1Overall survival benefitCochrane Central RegisterFirst-line treatmentPD-L1 statusPhase 3 trialLow PD-L1Absence of headSignificant differencesRandom-effects modelBayesian random-effects modelImproved PFSOS benefitEfficacy outcomesEligible trialsCentral Register
2014
Assessment of National Practice for Palliative Radiation Therapy for Bone Metastases Suggests Marked Underutilization of Single-Fraction Regimens in the United States
Rutter CE, Yu JB, Wilson LD, Park HS. Assessment of National Practice for Palliative Radiation Therapy for Bone Metastases Suggests Marked Underutilization of Single-Fraction Regimens in the United States. International Journal Of Radiation Oncology • Biology • Physics 2014, 91: 548-555. PMID: 25542310, DOI: 10.1016/j.ijrobp.2014.10.045.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseBone metastasesRadiation therapyMultiple fraction radiation therapyNon-private health insuranceSingle-fraction regimensPalliative radiation therapyProportion of patientsValue-based treatment decisionsRadiation therapy regimensMultiple-fraction treatmentsSingle-fraction treatmentCost-conscious careIndependent predictorsOsseous metastasesRandomized evidenceTherapy regimensLung cancerTreatment decisionsVertebral sitesClinical practicePatientsMarked underutilizationOlder ageSingle fraction
2011
Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update
Park HS, Chiang VL, Knisely JP, Raldow AC, Yu JB. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Review Of Anticancer Therapy 2011, 11: 1731-1738. PMID: 22050022, DOI: 10.1586/era.11.165.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsClinical Trials, Phase III as TopicCombined Modality TherapyHumansRadiosurgeryRandomized Controlled Trials as TopicConceptsWhole-brain radiation therapyStereotactic radiosurgeryBrain metastasesAddition of SRSUse of SRSMD Anderson Cancer CenterWhole brain radiotherapyLocal tumor controlStandard of careAnderson Cancer CenterNormal brain tissueNonrandomized evidenceLimited metastasesOligometastatic diseaseCancer CenterTumor controlRelative sparingRadiation therapyBrain tissueMetastasisSingle fractionNormal tissuesPatientsRadiosurgeryTrials